SG11201806696WA - Anti-citrullinated hla polypeptide antibodies and uses thereof - Google Patents
Anti-citrullinated hla polypeptide antibodies and uses thereofInfo
- Publication number
- SG11201806696WA SG11201806696WA SG11201806696WA SG11201806696WA SG11201806696WA SG 11201806696W A SG11201806696W A SG 11201806696WA SG 11201806696W A SG11201806696W A SG 11201806696WA SG 11201806696W A SG11201806696W A SG 11201806696WA SG 11201806696W A SG11201806696W A SG 11201806696WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rrcitaa
- qrcitaa
- michigan
- citrullinated
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000009870 specific binding Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
anthr.,;fs Affi.s• Etif):Ii. , Ant•i- , AP (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/139577 Al 17 August 2017 (17.08.2017) WIPO I PCT 111111111111110111011111111111010111110 011101111111100111111111111111111110111111 (51) International Patent Classification: A61K 38/08 (2006.01) A61K 38/10 (2006.01) (21) International Application Number: PCT/US2017/017373 (22) International Filing Date: 10 February 2017 (10.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/293,621 10 February 2016 (10.02.2016) US (71) Applicant: CAYMAN CHEMICAL COMPANY IN- CORPORATED [US/US]; 1180 East Ellsworth Road, Ann Arbor, Michigan 48108-2419 (US). (72) Inventor: MOBLEY, James Leslie; 10195 Covington, Brighton, Michigan 48116 (US). (74) Agent: ALBERDI, Fernando; 315 East Eisenhower Park- way, Suite 100, Ann Arbor, Michigan 48108-3330 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: ANTI-CITRULLINATED HLA POLYPEPTIDE ANTIBODIES AND USES THEREOF W O 20 17 / 139577 Al FIG. 1 (57) : The present invention relates to methods for treating an autoimmune disease in a human subject mediated by the presence of a citrullinated epitope QKCitAA, QRCitAA, or RRCitAA in the subject, the method comprising administering a thera- peutically effective amount of an antibody or a specific binding fragment thereof that specifically binds to citrullinated epitope QK - CitAA, QRCitAA, or RRCitAA. Further aspects of the invention include an antibody or a specific binding fragment thereof, that specifically binds to a human citrullinated epitope QKCitAA, QRCitAA, or RRCitAA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662293621P | 2016-02-10 | 2016-02-10 | |
PCT/US2017/017373 WO2017139577A1 (en) | 2016-02-10 | 2017-02-10 | Anti-citrullinated hla polypeptide antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806696WA true SG11201806696WA (en) | 2018-09-27 |
Family
ID=59563430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806696WA SG11201806696WA (en) | 2016-02-10 | 2017-02-10 | Anti-citrullinated hla polypeptide antibodies and uses thereof |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190048086A1 (en) |
EP (1) | EP3413905A4 (en) |
JP (1) | JP2019508415A (en) |
KR (1) | KR20180105710A (en) |
CN (1) | CN108883151A (en) |
AU (1) | AU2017217814A1 (en) |
BR (1) | BR112018016383A2 (en) |
CA (1) | CA3014079A1 (en) |
EA (1) | EA201891800A1 (en) |
IL (1) | IL260994A (en) |
MX (1) | MX2018009696A (en) |
PH (1) | PH12018501674A1 (en) |
SG (1) | SG11201806696WA (en) |
WO (1) | WO2017139577A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019101863A1 (en) | 2017-11-22 | 2019-05-31 | Vacara Ab | Antibodies to citrullinated proteins |
CA3129624A1 (en) * | 2019-02-15 | 2020-08-20 | Inova Diagnostics, Inc. | Compositions and methods for diagnosing and assessing rheumatoid arthritis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562943B1 (en) * | 1999-04-21 | 2003-05-13 | Zycos, Inc. | Peptide epitopes recognized by disease promoting CD4+ T lymphocytes |
US8198401B2 (en) * | 2003-03-07 | 2012-06-12 | London Health Sciences Centre Research Inc. | Peptides associated with HLA-DR MHC class II molecule and involved in rheumatoid arthritis |
TW200744634A (en) * | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
MY165625A (en) * | 2006-12-26 | 2018-04-18 | Ct Inmunologia Molecular | Pharmaceutical composition comprising an anti- cd6 monoclonal antibody useful for the diagnosis and treatment of rheumatoid arthritis |
DK2768851T3 (en) * | 2011-10-21 | 2017-09-18 | Augurex Life Sciences Corp | ANTIGENS DERIVED BY CITRULLINATED 14-3-3 AND APPLICATIONS THEREOF IN THE DIAGNOSIS OF RHEUMATOID ARTHRITIS |
JP2015506687A (en) * | 2012-01-19 | 2015-03-05 | セラピューティック プロテインズ インターナショナル, エルエルシー | Stabilization of the anti-CD20 antibody rituximab |
-
2017
- 2017-02-10 CA CA3014079A patent/CA3014079A1/en not_active Abandoned
- 2017-02-10 EA EA201891800A patent/EA201891800A1/en unknown
- 2017-02-10 CN CN201780018892.XA patent/CN108883151A/en active Pending
- 2017-02-10 US US16/076,599 patent/US20190048086A1/en not_active Abandoned
- 2017-02-10 EP EP17750831.4A patent/EP3413905A4/en not_active Withdrawn
- 2017-02-10 KR KR1020187025270A patent/KR20180105710A/en unknown
- 2017-02-10 MX MX2018009696A patent/MX2018009696A/en unknown
- 2017-02-10 JP JP2018542695A patent/JP2019508415A/en active Pending
- 2017-02-10 SG SG11201806696WA patent/SG11201806696WA/en unknown
- 2017-02-10 WO PCT/US2017/017373 patent/WO2017139577A1/en active Application Filing
- 2017-02-10 BR BR112018016383A patent/BR112018016383A2/en not_active IP Right Cessation
- 2017-02-10 AU AU2017217814A patent/AU2017217814A1/en not_active Abandoned
-
2018
- 2018-08-05 IL IL260994A patent/IL260994A/en unknown
- 2018-08-07 PH PH12018501674A patent/PH12018501674A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12018501674A1 (en) | 2019-06-10 |
IL260994A (en) | 2018-10-31 |
AU2017217814A1 (en) | 2018-08-23 |
CN108883151A (en) | 2018-11-23 |
EP3413905A1 (en) | 2018-12-19 |
KR20180105710A (en) | 2018-09-28 |
MX2018009696A (en) | 2018-11-09 |
JP2019508415A (en) | 2019-03-28 |
CA3014079A1 (en) | 2017-08-17 |
EA201891800A1 (en) | 2019-01-31 |
WO2017139577A1 (en) | 2017-08-17 |
EP3413905A4 (en) | 2019-07-24 |
BR112018016383A2 (en) | 2018-12-18 |
US20190048086A1 (en) | 2019-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201908092RA (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11201807677YA (en) | Antibodies to cd40 with enhanced agonist activity | |
SG11201907948TA (en) | Formulations comprising pd-1 binding proteins and methods of making thereof | |
SG11201906961UA (en) | Polypeptide variants and uses thereof | |
SG11201901597UA (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof |